A follow-up study of the prevalence of valvular heart abnormalities in hyperprolactinemic patients treated with cabergoline.

2.50
Hdl Handle:
http://hdl.handle.net/11287/619955
Title:
A follow-up study of the prevalence of valvular heart abnormalities in hyperprolactinemic patients treated with cabergoline.
Authors:
Drake, W M; Stiles, C E; Bevan, J S; Karavitaki, N; Trainer, P J; Rees, D A; Richardson, T I; Baldeweg, S E; Stojanovic, N; Murray, R D; Toogood, A A; Martin, N M; Vaidya, Bijay; Han, T S; Steeds, R P; Baldeweg, F C; Sheikh, U E; Kyriakakis, N; Parasuraman, S; Taylor, L; Butt, N; Anyiam, S
Abstract:
CONTEXT Uncertainty exists whether the long-term use of ergot-derived dopamine agonist (DA) drugs for the treatment of hyperprolactinemia may be associated with clinically significant valvular heart disease; and whether current regulatory authority guidelines for echocardiographic screening are clinically appropriate.
Citation:
A follow-up study of the prevalence of valvular heart abnormalities in hyperprolactinemic patients treated with cabergoline. 2016 Nov;101(11):4189-4194.
Publisher:
Endocrine Society
Journal:
The Journal of Clinical Endocrinology and Metabolism
Issue Date:
29-Aug-2016
URI:
http://hdl.handle.net/11287/619955
DOI:
10.1210/jc.2016-2224
PubMed ID:
27571182
Additional Links:
http://press.endocrine.org/doi/10.1210/jc.2016-2224?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed
Type:
Journal Article
Language:
en
ISSN:
1945-7197
Appears in Collections:
Diabetes/Endocrine Services; 2016 RD&E publications

Full metadata record

DC FieldValue Language
dc.contributor.authorDrake, W Men
dc.contributor.authorStiles, C Een
dc.contributor.authorBevan, J Sen
dc.contributor.authorKaravitaki, Nen
dc.contributor.authorTrainer, P Jen
dc.contributor.authorRees, D Aen
dc.contributor.authorRichardson, T Ien
dc.contributor.authorBaldeweg, S Een
dc.contributor.authorStojanovic, Nen
dc.contributor.authorMurray, R Den
dc.contributor.authorToogood, A Aen
dc.contributor.authorMartin, N Men
dc.contributor.authorVaidya, Bijayen
dc.contributor.authorHan, T Sen
dc.contributor.authorSteeds, R Pen
dc.contributor.authorBaldeweg, F Cen
dc.contributor.authorSheikh, U Een
dc.contributor.authorKyriakakis, Nen
dc.contributor.authorParasuraman, Sen
dc.contributor.authorTaylor, Len
dc.contributor.authorButt, Nen
dc.contributor.authorAnyiam, Sen
dc.date.accessioned2016-09-07T09:02:54Z-
dc.date.available2016-09-07T09:02:54Z-
dc.date.issued2016-08-29-
dc.identifier.citationA follow-up study of the prevalence of valvular heart abnormalities in hyperprolactinemic patients treated with cabergoline. 2016 Nov;101(11):4189-4194.en
dc.identifier.issn1945-7197-
dc.identifier.pmid27571182-
dc.identifier.doi10.1210/jc.2016-2224-
dc.identifier.urihttp://hdl.handle.net/11287/619955-
dc.description.abstractCONTEXT Uncertainty exists whether the long-term use of ergot-derived dopamine agonist (DA) drugs for the treatment of hyperprolactinemia may be associated with clinically significant valvular heart disease; and whether current regulatory authority guidelines for echocardiographic screening are clinically appropriate.en
dc.languageENG-
dc.language.isoenen
dc.publisherEndocrine Societyen
dc.relation.urlhttp://press.endocrine.org/doi/10.1210/jc.2016-2224?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmeden
dc.rightsArchived with thanks to The Journal of clinical endocrinology and metabolismen
dc.subjectWessex Classification Subject Headings::Endocrinologyen
dc.subjectWessex Classification Subject Headings::Cardiologyen
dc.titleA follow-up study of the prevalence of valvular heart abnormalities in hyperprolactinemic patients treated with cabergoline.en
dc.typeJournal Articleen
dc.identifier.journalThe Journal of Clinical Endocrinology and Metabolismen
dc.type.versionIn press (epub ahead of print)en

Related articles on PubMed

All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.